导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 31.84% | 74/4773 |
| 近一周 | -2.74% | 2966/5462 |
| 近一月 | -5.36% | 3187/5421 |
| 近一季 | -18.58% | 4732/5209 |
| 近半年 | 25.41% | 84/4920 |
| 近一年 | 48.92% | 71/4366 |
| 近两年 | 226.74% | 57/2954 |
| 近三年 | 218.46% | 8/2253 |
| 成立以来 | 134.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.22% 1339/4961 |
76.47% 190/5312 |
- - |
- - |
| 2025 | 92.50% 44/4813 |
-2.76% 2979/3635 |
6.37% 457/4076 |
74.45% 11/4524 |
6.69% 346/4813 |
| 2024 | 23.14% 348/3463 |
0.54% 958/2808 |
9.13% 58/3014 |
9.41% 2702/3129 |
2.58% 929/3463 |
| 2023 | 15.44% 35/2656 |
23.15% 118/2280 |
7.81% 25/2385 |
-12.27% 2114/2515 |
-0.90% 266/2655 |
| 2022 | -35.83% 1733/2207 |
-26.87% 1796/1919 |
3.29% 1177/2016 |
-18.64% 1729/2113 |
4.40% 551/2208 |
| 2021 | 6.35% 516/1822 |
-15.48% 1191/1255 |
20.45% 143/1330 |
-9.68% 1187/1466 |
15.68% 60/1822 |
| 2020 | 18.06% 748/1250 |
0.22% 167/1028 |
26.20% 147/1067 |
-5.30% 1109/1164 |
-1.44% 1106/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证5G通信主题ETF联接A VS. 长安沪深300非周期A(740101) |